18 juil. 2022 08h00 HE | Daxor Corporation
Company Received Funding from NIH to Accelerate New Clinical Decision Support Software For Use With Daxor’s Blood Volume Analyzer for Heart Failure Treatment Oak Ridge, TN, July 18, 2022 (GLOBE...
Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVID
14 juil. 2022 07h00 HE | Panacea Life Sciences Holdings, Inc.
GOLDEN, Colo., July 14, 2022 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) (“Panacea” or the “Company”), a Colorado, USA-based cannabinoid research-focused company providing...
Effective treatment is now available for millions suffering with long COVID symptoms
12 juil. 2022 10h01 HE | Aviv Clinics
ORLANDO, Fla., July 12, 2022 (GLOBE NEWSWIRE) -- Aviv Clinics highlights a groundbreaking new study that has been published in Scientific Reports, featuring a promising treatment for long COVID...
Truveta Announces Strategic Collaboration with Pfizer to Accelerate Safety Insights in Real Time
21 juin 2022 09h07 HE | Truveta
BELLEVUE, Wash., June 21, 2022 (GLOBE NEWSWIRE) -- Truveta today announced a strategic collaboration with Pfizer to deliver new safety insights on a continuous basis, using verifiable real-world...
Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients
25 mai 2022 08h00 HE | Daxor Corporation
Oak Ridge, TN, May 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of...
Flow Therapy Adds World-Renowned Cardiologist Timothy D. Henry to Board of Directors
06 avr. 2022 09h00 HE | Flow Therapy
FORT WORTH, Texas, April 06, 2022 (GLOBE NEWSWIRE) -- World-renowned cardiologist Timothy D. Henry, MD, FACC, MSCAI, has joined Flow Therapy's Board of Directors. Dr. Henry is the Lindner Family...
First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections
30 nov. 2021 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Highmark Interactive Announces Collaboration with Mayo Clinic to Assess Impact of "Long COVID" on Cognitive Function
05 oct. 2021 11h30 HE | Highmark Interactive
TORONTO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- BrainFx, a wholly owned subsidiary of Highmark Interactive, today announces its collaboration with Mayo Clinic to assess the impact of "Long COVID" or...
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
10 sept. 2021 08h30 HE | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies...
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
09 sept. 2021 08h30 HE | AzurRx BioPharma, Inc.
Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned Part 2 of RESERVOIR Trial to Enroll Up to 150 Patients to Evaluate Efficacy of FW-1022 and...